Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
2014 ASH Annual MeetingJulie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.
Related Videos
James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL
Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797,
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, T...
Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis
Richard M. Stone, MD, on the SAL-SORAML Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,
Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53,
